Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Seizures 2Glioma 2Epilepsy 1Drug Resistant Epilepsy 1Brain Neoplasms 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × perampanel × Clear all
NCT04497142 2024-08-05

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Dana-Farber Cancer Institute

Phase 1/2 Completed
12 enrolled 8 charts
CNS

Glioma, Seizures

NCT04650204 2023-06-22

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Mayo Clinic

Phase 4 Terminated
4 enrolled 9 charts
CNS

Drug Resistant Epilepsy, Epilepsy, Glioma

NCT02363933 2018-04-27

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Duke University

Phase 4 Completed
9 enrolled 9 charts
CNS

Brain Neoplasms, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon âš¡